Artelo Biosciences initiated with a Buy at EF Hutton

EF Hutton initiated coverage of Artelo Biosciences with a Buy rating and $6 price target Artelo is an emerging biotechnology company focused on cachexia and chemotherapy-induced peripheral neuropathy, the analyst tells investors in a research note. The firm says the company is early in its growth phase, and raising capital will be mission-critical to realize the next series of value inflection points.